Sight Sciences, Inc.
Sight Sciences, Inc. develops and commercializes interventional ophthalmic technologies used by eye care providers to treat glaucoma and dry eye disease. Its portfolio includes surgical devices for glaucoma procedures and the TearCare system for dry eye treatment, sold primarily in the United States with additional international distribution in select European markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInterventional devices used by ophthalmic surgeons in glaucoma procedures, including OMNI and SION.
TearCare systems, SmartHubs, SmartLids, and related accessories for dry eye treatment.
Customers
Sight Sciences sells primarily to eye care providers, including ophthalmologists, optometrists, ambulatory surgery centers, and hospital outpatient departments. Its glaucoma products are used in procedural settings, while TearCare is purchased by practices that treat dry eye patients and reorder consumables over time.
Buy OMNI and SION for outpatient glaucoma procedures and value devices that fit procedural workflows.
Purchase glaucoma devices and TearCare systems to expand treatment options for eye disease patients.
Buy TearCare for dry eye treatment and recurring SmartLid consumables.
Influence adoption through reimbursement and coverage decisions for TearCare and related procedures.
Strategy
Sight Sciences is focused on expanding adoption of its interventional eye care technologies by building clinical evidence, improving reimbursement access, and increasing provider awareness. It is also investing in commercial coverage, education, and international expansion while continuing to develop new products for glaucoma and ocular surface disease.
Coverage decisions are central to patient access and adoption in dry eye.
The products require specialized training and consultative selling to drive procedural adoption.
Geographic expansion can diversify revenue and extend the installed base.
Pipeline innovation supports long-term relevance in glaucoma and ocular surface disease.
Geography
The company generates substantially all of its revenue in the United States, where its direct sales organization is concentrated. It also sells OMNI in select European countries through distributors and maintains direct sales in Germany and the United Kingdom, making reimbursement and market access important in both U.S. and European markets.
Risks
The business depends on reimbursement, physician adoption, and continued clinical differentiation in highly competitive ophthalmic markets. It also relies on third-party manufacturing, including significant sourcing from China and single-source suppliers, which creates supply chain, tariff, and quality risks.
- Reimbursement and coverage riskImpact: HighLikelihood: High
TearCare adoption depends on payor coverage and coding status.
Exposure: Dry Eye segment
- Competitive pressure in MIGS and dry eyeImpact: HighLikelihood: High
Larger and better-capitalized rivals can offer alternative devices and procedures.
Exposure - Third-party manufacturing and supply chain concentrationImpact: HighLikelihood: High
The company relies on external manufacturers and many components are single-source.
Exposure - Early-stage operating lossesImpact: HighLikelihood: High
The company expects continued losses while investing in commercialization and product development.
Exposure: Enterprise-wide
- China sourcing and tariff exposureImpact: MediumLikelihood: High
A substantial portion of products and components are manufactured in China.
Exposure: Imported components and finished goods
Accounting
Judgemental itemsSales include capital equipment and consumables, which may recognize at different points in time.
Impact: Affects quarterly revenue mix and comparability
A meaningful non-cash expense for a growth-stage medical device company.
Impact: Affects operating expense and net loss
Term loan interest, issuance costs, and extinguishment charges can materially affect results.
Impact: Affects interest expense and below-operating items
Demand can be lower in summer and winter holiday periods due to provider scheduling.
Impact: Affects quarterly revenue and margin comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Alcon Inc
ALC · Ophthalmic Goods
Alcon Inc is a United States-based ophthalmic goods company focused on eye care products and surgical ophthalmology solutions.
RetinalGenix Technologies Inc.
RTGN · Surgical & Medical Instruments & Apparatus
STAAR Surgical Company
STAA · Ophthalmic Goods
STAAR Surgical designs, manufactures, and sells implantable lenses for the eye and the accessory delivery systems used to place them.
LENSAR, Inc.
LNSR · Surgical & Medical Instruments & Apparatus
IRIDEX Corporation
IRIX · Electromedical & Electrotherapeutic Apparatus
IRIDEX Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems and related therapies for sight-threatening eye diseases.
OSI Systems, Inc
OSIS · Semiconductors & Related Devices
Last updated: 24/09/2026